	Application No.	Applicant(s)
Notice of Allowability	, ippinediaent ite.	, Applicating of
	10/634,961	PALESE ET AL.
	Examiner	Art Unit
	Mary E. Mosher, Ph.D.	1648
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>9/22/2005.</u>		
2. ☑ The allowed claim(s) is/are <u>6-10</u> .		
3. Acknowledgment is made of a claim for foreign priority un  a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)  1. Notice of References Cited (PTO-892)	E  Alatina of Informal D	otant Application (DTO 450)
Notice of References Cited (PTO-992)     Notice of Draftperson's Patent Drawing Review (PTO-948)		atent Application (PTO-152)
	6.  ☐ Interview Summary Paper No./Mail Dat	(P10-413), e
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date</li> </ol>	Paper No./Mail Dat 8), 7. ⊠ Examiner's Amendn	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8.   Examiner's Stateme	nt of Reasons for Allowance
•	9.	

Application/Control Number: 10/634,961 Page 2

Art Unit: 1648

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

The paragraphs from specification page 8, line 23 to page 9, line 5, were replaced with the following single paragraph, to remove reference to nonexistent parts of Figure 8 for consistency with the patented parent.

Figure 8. The VP35 protein of Ebola virus inhibits induction of the IFN- $\beta$  promoter. Inhibition of induction of the mouse IFN-  $\beta$  promoter. 293 cells were transfected with 4 μg of the indicated expression plasmid plus 0.3 μg each of the reporter plasmids pIFN- $\beta$ -CAT and pGL2-Control. Twenty-four hours posttransfection, the cells were mock-transfected or transfected with 40 μg of polyl:polyC.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-272-0906. The examiner can normally be reached on Monday-Thursday and alternate Fridays.

Application/Control Number: 10/634,961

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

12/9/05

PRIMARY EXAMINER

Page 3